MedTrace Logo

First-into-human Study of NS-136 in Healthy Subjects

NCT06345703 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-11-19

No results posted yet for this study

Summary

The goal of this clinical trial is to exlplore the profile of NS-136 in health conditions. The main questions it aims to answer are:

* Is NS-136 safe and tolerable in heathy subjects under tested dosing regimen?
* What is the pharmacokinectic profile of NS-136 in healthy subjects under tested dosing regimen?

Conditions

  • Healthy Subjects

Interventions

DRUG

Placebo

NS-136 matching placebo

DRUG

NS-136 tablet

Investigational product NS-136

Sponsors & Collaborators

  • NeuShen Therapeutics

    lead INDUSTRY

Principal Investigators

  • Emir Redzepagic, MD · CMAX Clinical Research Pty Ltd

  • Xiaolan Yong Chief Pharmacist, BS · Chengdu Xinhua Hospital, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2024-11-30
Completion
2025-02-28

Countries

  • Australia
  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06345703 on ClinicalTrials.gov